部份中文奥扎格雷钠处方资料（仅供参考）
英文药名：Ozagrel Na Inj（Ozagrel Sodium）
中文药名：奥扎格雷钠注射剂
生产厂家：日本医药工业有限公司
药品介绍
オザグレルＮａ点滴静注液２０ｍｇ「ケミファ」/*オザグレルＮａ点滴静注液４０ｍｇ「ケミファ」/*オザグレルＮａ点滴静注液８０ｍｇ「ケミファ」
药物分类名称
血栓烷合成酶抑制剂
批准日期：
商標名
一般名：
オザグレルナトリウム (Ozagrel Sodium)
化学名：
Monosodium (2E )-3-［4-(1H -imidazol-1-ylmethyl) phenyl］prop-2-enoate
分子式：
C13H11N2NaO2
分子量：
250.23
構造式：
性状
奥扎格雷钠是白色晶体或结晶粉末。
该产品易溶于水，微溶于甲醇，几乎不溶于乙醇（99.5）。
处理注意事项
稳定性测试2）
Ozagrel Na输液静脉注射液20 mg“Chemiphas”·Ozagrel Na滴注液40 mg“Chemiphar”
使用浅棕色透明玻璃安瓿（无包装·遮光状态）进行长期储存试验（25℃，3年），确认在正常市场流通下稳定3年。
奥扎格雷钠滴注液80毫克“Chemiphar”：
使用浅棕色透明玻璃安瓿（未包装·遮光状态）进行加速试验（40℃，6个月），推断出在正常市场流通下稳定3年。
药用药理学
对脑梗塞的作用
在大鼠大脑中动脉闭塞/再开放模型中以100μg/kg/min的速率连续静脉内施用奥扎格雷钠24小时后显示出抑制脑梗塞病变形成的效果。
适应症
1.蛛网膜下腔出血后脑血管痉挛的改善及脑缺血的相关症状
2.改善与脑血栓形成相关的运动障碍（急性期）
用法与用量
1.蛛网膜下腔出血后脑血管痉挛的改善及脑缺血的相关症状
对于成人，每天80mg作为奥扎格雷钠用适量的电解质溶液或糖溶液稀释，并在24小时内连续静脉内施用。 应在蛛网膜下腔出血后早期开始给药，并且希望继续给药2周。
另外，应根据您的年龄和症状增加或减少。
2.改善与脑血栓形成相关的运动障碍（急性期）
对于成人，用奥扎格雷钠稀释80毫克一次作为奥扎格雷钠和适量的电解质溶液或糖溶液，并在早晨连续静脉内输注两次，持续2小时，持续约2周。
另外，应根据您的年龄和症状增加或减少。
包装
Na输注IV溶液
20mg：10安瓿，50安瓿
40mg：10安瓿，50安瓿
80mg：10安瓿
制造供应商
制造供应商
日本医药工业有限公司
注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整资料附件：http://www.info.pmda.go.jp/go/pack/3999411A3079_1_02/
Ozagrel sodium
Japan. Ozagrel sodium, a thromboxane synthesis enzyme inhibitor, was approved in January 1988 for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia. Thereafter an additional indication for improvement of motility disturbance due to acute cerebral thrombosis was approved in April 1992.
PRODUCT NAME: Ozagrel Sodium for Injection
DESCRIPTION:
Ozagrel Sodium for Injection is white or whitish lyophilized cake.
INDICATIONS: Used for the treatment of acute thrombotic cerebral infarction or disturbance on motor functions.
ADMINISTRATION AND DOSAGE:
For adult: 80mg, twice a day, solute in 500ml normal saline or 5% glucose solution, intravenous infusion, treatment durationis 2 weeks.
ADVERSE EFFECTS:
Blood: Because of bleeding tendency, careful observation is needed. Stop the administration once such abnormal symptomappearsLiver and kidney: Occasional increase of GOT, GPT, BUNDigestive system: Occasional nausea, vomiting, diarrhea, anorexia, abdominal distention.
Allergic effects: Occasional urticaria, skin rash, etc., stop the administration once such effects spotted.
Circulation system: Occasional supraventricular arrhythmia and hypotension, once such symptom appears, decrease theamount or stop the administration.
Others: Occasional headache, fever, pain at the injection site, shock orthrombocytopenia.
Server adverse effects can be hemorrhagic cerebral infarction, extradural hemorrhage, encephalic hemorrhage,gastrointestinal hemorrhage, subcutaneous hemorrhage, etc.
CONTRADICTIONARIES:
The patients with following symptoms:
1. Allergic to ozagrel;
2. Cerebral hemorrhage or cerebral infarction with hemorrhage, deep coma accompanied large area cerebral infarction;
3. Severe impairment on heart, lung, liver, kidney, such as severe arrhythmia or cardiovascular infarction;
4. Hemopathy or hemorrhagic tendency;
5. Severe hypertension, with a contracting pressure of 200mmHg.
PRECAUTIONS:
Avoid mixing use of Ozagrel Sodium for Injection and solution containing calcium (Green's solution) in case there will bewhite turbidity.
PREGNANCY AND LACTATION: Pregnant women should be administered with Ozagrel Sodium for Injection with extremecare; Other usages haven't been found out yet.GERIATRIC USE: Because of the low biological activity, the elder should be administered with Ozagrel Sodium for Injectionwith extreme care.
DRUG INTERACTIONS: When used with platelet anti-coagulant, thrombosis dissolutant or other anti-coagulants,hemorrhagic tendency can be increased, therefore it should be used with extreme care. If necessary, the dose can bedecreased.
OVERDOSAGE: Once the over-dosage happens, specific treatment should be granted to different symptoms, but the focusis to monitor the hemorrhage and coagulation and to deal with them promptly.
SPECIFICATIONS: 20mg (counted by ozagrel sodium C13H11N2NaO2)
STORAGE: Kept in dark with closure.
PACKAGING: Colorless glass tube for antibiotics
EXPIRATION PERIOD: 24 months